EUCTR2004-001000-12-SK进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Phase II,Exploratory Evaluation of a Single Dose of ALGRX 4975 in Subjectswith Acute Lateral Epicondylitis
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subjects of either gender, aged 18 - 75 years.
- •2.Subjects with acute lateral epicondylitis (LE) of less than 3 months’ duration (subjects with recurrent acute LE may be included) with the following characteristics:
- •?pain on palpation of the epicondyle and/or the common extensor mass
- •?pain on wrist pronation and dorsiflexion against resistance with the elbow in extension
- •?pain reproduced by static stretching of the pronated wrist in palmar flexion with the elbow in extension
- •?Normal anterior-posterior and lateral X-ray films of the elbow
- •3.Subjects with a screening (Visit 1) and baseline (Visit 2) severity of pain on resisted wrist dorsiflexion score of moderate or greater intensity.
- •4.Subjects who are lidocaine responsive, as confirmed by an injection of lidocaine to the most tender spot at the screening visit. Only subjects who are totally pain free 15 minutes after the injection of lidocaine (2.5 mL of 2% lidocaine) will be allowed to enter the study. If the patient remains pain free at the baseline visit, he/she will not be eligible to participate in the study.
- •5.The subject has a systolic and diastolic blood pressure not greater than 140 and 95 mm Hg, respectively
- •6.Subjects who have provided written informed consent which has been approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB).
- •7.Female subjects of childbearing potential with a negative serum pregnancy test prior to entry into the study. Female subjects may be included without a negative serum pregnancy test if they are surgically sterile or at least 2 years post-menopausal.
- •8.Ability to understand the requirements of the study, abide by the study restrictions and agree to return for the required assessments.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.The subject has a clinically significant form of joint disease at the elbow, other than acute LE.
- •2.Subjects with a history of elbow trauma in the last 2 years.
- •3.Subjects who are undergoing physiotherapy treatment within the preceding 2 weeks, prior to Visit 1.
- •4.Subjects with a history of rheumatoid, inflammatory, degenerative, polyarthritis, metabolic/crystal-induced or infectious arthritis, or carpal tunnel syndrome.
- •5.Subjects who have received any systemic or local corticosteroids within the preceding 3 months, except nasal or inhaled steroids at ? 1000 ?g/day.
- •6.The subject has a medical condition other then LE that requires the use of a pain medication (e.g., fibromyalgia, inflammatory arthritis, musculoskeletal or articular disorder or any congenital, direct traumatic, crystal-induced, metabolic, infectious or immune-related disorder).
- •7.The subject has a medical condition that in the Investigator’s opinion could adversely impact their participation or safety, conduct of the study, or interfere with the pain assessments.
- •8.The subject has active cutaneous infection, trauma, or clinically significant form of disease at the anticipated site of injection.
- •9.The subject used an analgesic, other than aspirin for cardiovascular prophylaxis, during the washout period that could confound the analgesic response.
- •10.Subjects with any neuromuscular disorder affecting the area, including radial or ulnar nerve entrapment, or tumor.
- •11.Subjects in whom the use of lidocaine, capsaicin or paracetamol is contraindicated (e.g., significant history of allergic reactions or intolerance to these or related substances).
- •12.The subject has a peripheral sensory or motor neuropathy involving the upper extremities.
- •13.The subject is taking an antihypertensive agent, antidepressant, or anticonvulsant that has not been stable for at least 2 months.
- •14.The subject is diabetic and has not been on a stable diabetic regimen for the past 2 months.
- •15.Female subjects who are pregnant or lactating.
- •16.Female subjects of childbearing potential who are not practicing an effective method of contraception.
- •17.The subject has taken any investigational medication within 3 months prior to the first dose of study drug (Visit 2), or is scheduled to receive an investigational drug other than ALGRX 4975 while participating in the study.
- •18.Subjects who have previously entered this study.
- •19.The subject has a history of drug or alcohol abuse within the past 2 years.
研究者
相似试验
进行中（未招募）
1 期
Myelofibrosis: Phase 3 Study of Navitoclax Plus Ruxolitinib Versus RuxolitinibMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MyelofibrosisEUCTR2020-000097-15-SEAbbVie Deutschland GmbH & Co. KG230
进行中（未招募）
1 期
A study of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Soft Tissue SarcomaAdvanced or Metastatic Soft Tissue SarcomaMedDRA version: 20.0Level: HLTClassification code 10041298Term: Soft tissue sarcomas histology unspecifiedSystem Organ Class: 100000004864EUCTR2015-000134-30-PLEli Lilly and Company460
进行中（未招募）
1 期
Myelofibrosis: Phase 3 Study of Navitoclax Plus Ruxolitinib Versus RuxolitinibMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MyelofibrosisEUCTR2020-000097-15-BEAbbVie Deutschland GmbH & Co. KG230
进行中（未招募）
1 期
A study to determinate the safety and efficacy of LY3471851 in Adult Patients with Systemic Lupus ErythematosusMedDRA version: 21.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2019-003323-38-DEEli Lilly & Company280
进行中（未招募）
1 期
A study to assess whether different doses of KVD824 are effective in preventing attacks of Hereditary Angiodedema Type I or Type II.Hereditary Angioedema Type I or IIMedDRA version: 21.0Level: LLTClassification code 10080956Term: Hereditary angioedema type ISystem Organ Class: 100000004850MedDRA version: 24.0Level: LLTClassification code 10080960Term: Hereditary angioedema type IISystem Organ Class: 100000004850EUCTR2021-000136-59-BGKalvista Pharmaceuticals Ltd48